Work

Case Report: Abiraterone in brain metastases from prostate cancer

Year: 2025

Type: article

Abstract: Background: Prostate carcinoma (PC) is the most common cancer in men worldwide. However, brain metastases (BM) from prostate cancer are extremely rare events, usually in the later course of the disease. There is no established standard of care treatment for this situation. The efficacy of androgen synthesis inhibitor abiraterone in BM from PC is unknown. Case: We herein report the case of an 83-year-old patient with metastatic hormone-sensitive PC who had multiple BM at primary diagnosis, clinically manifesting with dizziness, ataxia, and unsteady gait. Combination of abiraterone and androgen deprivation therapy showed exceptional sustained cerebral tumor response. After 12 months of treatment, the patient is asymptomatic with an excellent performance status. Conclusion: Symptomatic BM from PC is a rarity but can show sustained response to abiraterone and androgen deprivation therapy. After comprehensive literature search, there is no comparable case published to date.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1555897

Authors: Tobias Peres, Stefanie Aeppli, Stefanie Fischer, Christian Rothermundt

Institutions: Kantonsspital St. Gallen, Luzerner Kantonsspital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801